Aerosolizable Janus Protein Nanoparticles for Secondary and Tertiary Lung Cancer Chemoprevention

Squamous cell carcinoma of the lung (LUSC) arises in the upper large airways of the lung. While this location appears to be readily accessible, barriers such as mucus, cilia, and resident phagocytes can limit the efficacy of inhaled chemopreventive agents. Adding to the challenges, aerosolization methods such as nebulization often induce mechanical and thermal stresses that can compromise the integrity of therapeutics and vehicles. Here, we report the aerosolization of anisotropic Janus protein nanoparticles (JNPs) prepared via electrohydrodynamic (EHD) co-jetting for co-delivery of the apolar molecule fenretinide (4HPR) and the monoclonal antibody tocilizumab (TCZ). Our findings show that JNPs experienced a marginal increase in diameter after aerosolization, from 391.3 ± 152.5 nm to 419.9 ± 168.4 nm. Scanning electron microscopy (SEM) and super-resolution confocal microscopy results confirmed minimal changes to particle morphology and preservation of the bicompartmental nature of JNPs. Furthermore, a dose-dependent study revealed that JNPs exhibit good stability in aerosols, which can be leveraged to adjust and maximize payload regardless of particle concentration. We further confirmed the retention of the therapeutics' bioactivity in vitro after aerosolization based on activation of caspase-3-mediated apoptosis and reduction of IL-6-induced STAT3-mediated signaling (via p-STAT3). Aerosolization of JNPs combines stability and preservation of biological function, and their bicompartmental design can be leveraged for further applications in co-delivery of synergistic drug combinations.

Authors

Institutions

Publication Details

Journal
ACS Applied Bio Materials
Published
2026-11-17
DOI
https://doi.org/10.1021/acsabm.6c01387
Primary Topic
Inhalation and Respiratory Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Aerosolizable Janus Protein Nanoparticles for Secondary and Tertiary Lung Cancer Chemoprevention

Joerg Lahann, Fortune Shea, Susan R. Mallery, Aditya Kishan et al.
2 links
ACS Applied Bio Materials
Inhalation and Respiratory Drug Delivery
article

Aerosolizable Janus Protein Nanoparticles for Secondary and Tertiary Lung Cancer Chemoprevention

Joerg Lahann, Fortune Shea, Susan R. Mallery, Aditya Kishan, Albert Chang, Daren Wang, Josh Flint
article en

Abstract

Squamous cell carcinoma of the lung (LUSC) arises in the upper large airways of the lung. While this location appears to be readily accessible, barriers such as mucus, cilia, and resident phagocytes can limit the efficacy of inhaled chemopreventive agents. Adding to the challenges, aerosolization methods such as nebulization often induce mechanical and thermal stresses that can compromise the integrity of therapeutics and vehicles. Here, we report the aerosolization of anisotropic Janus protein nanoparticles (JNPs) prepared via electrohydrodynamic (EHD) co-jetting for co-delivery of the apolar molecule fenretinide (4HPR) and the monoclonal antibody tocilizumab (TCZ). Our findings show that JNPs experienced a marginal increase in diameter after aerosolization, from 391.3 ± 152.5 nm to 419.9 ± 168.4 nm. Scanning electron microscopy (SEM) and super-resolution confocal microscopy results confirmed minimal changes to particle morphology and preservation of the bicompartmental nature of JNPs. Furthermore, a dose-dependent study revealed that JNPs exhibit good stability in aerosols, which can be leveraged to adjust and maximize payload regardless of particle concentration. We further confirmed the retention of the therapeutics' bioactivity in vitro after aerosolization based on activation of caspase-3-mediated apoptosis and reduction of IL-6-induced STAT3-mediated signaling (via p-STAT3). Aerosolization of JNPs combines stability and preservation of biological function, and their bicompartmental design can be leveraged for further applications in co-delivery of synergistic drug combinations.

ACS Applied Bio Materials
University of Michigan (US), The Ohio State University (US)
National Cancer Institute
Good health and well-being
Inhalation and Respiratory Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon